Regenerative nanomedicine for vision restoration

Mayo Clinic Proceedings

Volumn 88, Issue 12, 2013, Pages 1480-1490

  Zarbin, Marco A ^a   Arlow, Timothy ^a   Ritch, Robert ^b,c  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIUM OXIDE; CHITOSAN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ION CHANNEL; LIPOSOME; MEMBRANE PROTEIN; NANOPARTICLE; PIGMENT EPITHELIUM DERIVED FACTOR; POLYCAPROLACTONE; PROTEIN FLT23K; QUATERNARY AMMONIUM DERIVATIVE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VERTEPORFIN; ADRENALIN HYDROGEN TARTRATE; HALORHODOPSIN; MACROGOL; PIGMENT EPITHELIUM-DERIVED FACTOR; SMALL INTERFERING RNA;

CONFERENCE PAPER; CONTACT LENS; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; EYE DISEASE; FLT23K GENE; GENE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HUMAN; INTRAOCULAR PRESSURE; MOLECULAR MECHANICS; NANOELECTROMECHANICAL SYSTEM; NANOMEDICINE; NONHUMAN; OPTIC NERVE LESION; OPTOGENETICS; PHOTODYNAMIC THERAPY; REGENERATIVE MEDICINE; RETINA DEGENERATIVE DISEASE; RETINA DISEASE; RETINA NEOVASCULARIZATION; SENSOR; SUBRETINAL NEOVASCULARIZATION; BLINDNESS; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; EYE DISEASES; NANOTECHNOLOGY; OPTIC NERVE DISEASES; PATHOPHYSIOLOGY; RETINAL DEGENERATION; RETINAL NEOVASCULARIZATION; VISION; VISION DISORDERS; AAQ; ACRYLAMIDE-AZOBENZENE-QUATERNARY AMMONIUM; CHANNELRHODOPSIN-2; CHOROIDAL NEW VESSEL; CHR2; CNV; ECM; EXTRACELLULAR MATRIX; HALOR; OPTIC NERVE DISEASE; PCL; PEG; PIGMENT EPITHELIUM; POLY(Ε-CAPROLACTONE); RETINA DEGENERATION; RETINA GANGLION CELL; REVIEW; RGC; RPE; VISUAL DISORDER;

BLINDNESS; CHOROIDAL NEOVASCULARIZATION; EYE DISEASES; HUMANS; INTRAOCULAR PRESSURE; NANOMEDICINE; NANOTECHNOLOGY; OPTIC NERVE DISEASES; REGENERATIVE MEDICINE; RETINAL DEGENERATION; RETINAL NEOVASCULARIZATION; VISION DISORDERS; VISION, OCULAR;

AAQ; ACRYLAMIDE-AZOBENZENE-QUATERNARY AMMONIUM; CHANNELRHODOPSIN-2; CHOROIDAL NEW VESSEL; CHR2; CNV; ECM; EXTRACELLULAR MATRIX; GDNF; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HALOR; HALORHODOPSIN; INTRAOCULAR PRESSURE; IOP; PCL; PEDF; PEG; PIGMENT EPITHELIUM-DERIVED FACTOR; POLY(Ε-CAPROLACTONE); POLYETHYLENE GLYCOL; RETINAL GANGLION CELL; RETINAL PIGMENT EPITHELIUM; RGC; RPE; SHORT HAIRPIN RNA; SHRNA; SIRNA; SMALL INTERFERING RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

EID: 84893009253     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.05.025     Document Type: Conference Paper

References (80)

1. Prow T, Salazar JH, Rose WA, et al. Nanomedicine-nanoparticles, molecular biosensors and targeted gene/drug delivery for combined single-cell diagnostics and therapeutics. Proc SPIE. 2004;5318:1-11.
2. Prow T, Grebe R, Merges C, et al. Nanoparticle tethered antioxidant response element as a biosensor for oxygen induced toxicity in retinal endothelial cells. Mol Vis. 2006;12:616-625.
3. Prow TW, Bhutto I, Grebe R, et al. Nanoparticle-delivered biosensor for reactive oxygen species in diabetes. Vision Res. 2008;48(3):478-485.
4. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol. 2010; 150(2):144-162.e2.
5. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanotechnology in ophthalmology. Can J Ophthalmol. 2010;45(5):457-476.
6. Zarbin MA, Montemagno C, Leary JF, Ritch R. Regenerative nanomedicine and the treatment of degenerative retinal diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012; 4(1):113-137.
7. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine for the treatment of retinal and optic nerve diseases. Curr Opin Pharmacol. 2013;13(1):134-148.
8. Zarbin M, Montemagno C, Leary J, Ritch R. Artificial vision. Panminerva Med. 2011;53(3):167-177.
9. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol. 2006;1(2):142-150.
10. Zhou X, Wong LL, Karakoti AS, Seal S, McGinnis JF. Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the vldlr knockout mouse. PLoS One. 2011;6(2):e16733.
11. Cai X, Sezate SA, Seal S, McGinnis JF. Sustained protection against photoreceptor degeneration in tubby mice by intravitreal injection of nanoceria. Biomaterials. 2012;33(34):8771-8781.
12. Kong L, Cai X, Zhou X, et al. Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways. Neurobiol Dis. 2011;42(3):514-523.
13. Han Z, Conley SM, Makkia RS, Cooper MJ, Naash MI. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest. 2012;122(9):3221-3226.
14. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One. 2009;4(4):e5290.
15. Koirala A, Makkia RS, Cooper MJ, Naash MI. Nanoparticlemediated gene transfer specific to retinal pigment epithelial cells. Biomaterials. 2011;32(35):9483-9493.
16. Han Z, Koirala A, Makkia R, Cooper MJ, Naash MI. Direct gene transfer with compacted DNA nanoparticles in retinal pigment epithelial cells: expression, repeat delivery and lack of toxicity. Nanomedicine (Lond). 2012;7(4):521-539.
17. Ding XQ, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, Naash MI. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One. 2009; 4(10):e7410.
18. Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res. 2008;68(5):1247-1250.
19. Chen CW, Lu DW, Yeh MK, Shiau CY, Chiang CH. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine. 2011;6:2567-2580.
20. Suen W-LL, Chau Y. Specific uptake of folate-decorated triamcinolone-encapsulating nanoparticles by retinal pigment epithelium cells enhances and prolongs antiangiogenic activity. J Control Release. 2013;167(1):21-28.
21. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for agerelated macular degeneration: an integrated survey of emerging treatment alternatives. Retina. 2010;30(9):1350-1367.
22. Luo L, Zhang X, Hirano Y, et al. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano. 2013;7(4):3264-3275.
23. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dualtargeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009;16(5):645-659.
24. Gross N, Ranjbar M, Evers C, et al. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol Vis. 2013;19:54-61.
25. Akiyama G, Sakai T, Kuno N, et al. Photoreceptor rescue of pigment epithelium-derived factor-impregnated nanoparticles in Royal College of Surgeons rats. Mol Vis. 2012;18:3079-3086.
26. Gal A, Li Y, Thompson DA, et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet. 2000;26(3):270-271.
27. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006;103(10):3896-3901.
28. Sakai T, Kuno N, Takamatsu F, et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in Royal College of Surgeons rats. Invest Ophthalmol Vis Sci. 2007;48(7):3381-3387.
29. Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis. 2007;13:1783-1792.
30. Checa-Casalengua P, Jiang C, Bravo-Osuna I, et al. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Release. 2011;156(1):92-100.
31. Du J, Zhao W, Wang Y, Cai Y. Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization. J Ocular Pharmacol Ther. 2013;29(1):14-22.
32. Jani PD, Singh N, Jenkins C, et al. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2007;48(5): 2030-2036.
33. Owen LA, Uehara H, Cahoon J, Huang W, Simonis J, Ambati BK. Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One. 2012;7(3):e33576.
34. Lai CM, Estcourt MJ, Wikstrom M, et al. rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci. 2009;50(9):4279-4287.
35. Cho YK, Uehara H, Young JR, et al. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci. 2012;53(4):2328-2336.
36. Qazi Y, Stagg B, Singh N, et al. Nanoparticle-mediated delivery of shRNA: VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci. 2012;53(6):2837-2844.
37. Montana CL, Kolesnikov AV, Shen SQ, Myers CA, Kefalov VJ, Corbo JC. Reprogramming of adult rod photoreceptors prevents retinal degeneration. Proc Natl Acad Sci U S A. 2013; 110(5):1732-1737.
38. Winkler JL, Kedees MH, Guz Y, Teitelman G. Inhibition of connective tissue growth factor by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy. Mol Vis. 2012;18:874-886.
39. Su Y, Yang CY, Li Z, et al. Smad7 siRNA inhibit expression of extracellular matrix in trabecular meshwork cells treated with TGF-b2. Mol Vis. 2012;18:1881-1884.
40. Busskamp V, Picaud S, Sahel JA, Roska B. Optogenetic therapy for retinitis pigmentosa. Gene Ther. 2012;19(2):169-175.
41. Ahuja AK, Dorn JD, Caspi A, et al. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. 2011;95(4): 539-543.
42. Zhang H, Morrison MA, Dewan A, et al. The NEI/NCBI dbGAP database: genotypes and haplotypes that may specifically predispose to risk of neovascular age-related macular degeneration. BMC Med Genet. 2008;9:51.
43. Tomita H, Sugano E, Yawo H, et al. Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. Invest Ophthalmol Vis Sci. 2007; 48(8):3821-3826.
44. Bi A, Cui J, Ma YP, et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron. 2006;50(1):23-33.
45. Doroudchi MM, Greenberg KP, Liu J, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther. 2011; 19(7):1220-1229.
46. Lagali PS, Balya D, Awatramani GB, et al. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci. 2008;11(6):667-675.
47. Zhang Y, Ivanova E, Bi A, Pan ZH. Ectopic expression of multiple microbial rhodopsins restores ON and OFF light responses in retinas with photoreceptor degeneration. J Neurosci. 2009;29(29):9186-9196.
48. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science. 2010;329(5990):413-417.
49. Kleinlogel S, Feldbauer K, Dempski RE, et al. Ultra light-sensitive and fast neuronal activation with the Ca2+-permeable channelrhodopsin CatCh. Nat Neurosci. 2011;14(4):513-518.
50. Lin JY. Optogenetic excitation of neurons with channelrhodopsins: light instrumentation, expression systems, and channelrhodopsin variants. Prog Brain Res. 2012;196:29-47.
51. Caporale N, Kolstad KD, Lee T, et al. LiGluR restores visual responses in rodent models of inherited blindness. Mol Ther. 2011;19(7):1212-1219.
52. Polosukhina A, Litt J, Tochitsky I, et al. Photochemical restoration of visual responses in blind mice. Neuron. 2012;75(2):271-282.
53. Pearson RA, Barber AC, Rizzi M, et al. Restoration of vision after transplantation of photoreceptors. Nature. 2012;485(7396): 99-103.
54. de Lima S, Koriyama Y, Kurimoto T, et al. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. Proc Natl Acad Sci U S A. 2012; 109(23):9149-9154.
55. Dai C, Khaw PT, Yin ZQ, Li D, Raisman G, Li Y. Structural basis of glaucoma: the fortified astrocytes of the optic nerve head are the target of raised intraocular pressure. Glia. 2012;60(1):13-28.
56. Dai C, Khaw KT, Yin C, Li D, Raisman G, Li Y. Olfactory ensheathing cells rescue optic nerve fibers in a rat glaucoma model. Trans Vis Sci Tech. 2012;1(2):3.
57. Zarbin M. The promise of stem cells for age-related macular degeneration and other retinal degenerative diseases. Drug Discovery Today Ther Strategies. 2012. http://dx.doi.org/10.1016/ j.ddstr.2012.08.001. Accessed July 30, 2013.
58. Cai S, Smith ME, Redenti SM, Wnek GE, Young MJ. Mouse retinal progenitor cell dynamics on electrospun poly (e-caprolactone). J Biomater Sci Polym Ed. 2011;22(4-6):443-456.
59. Christiansen AT, Tao SL, Smith M, et al. Subretinal implantation of electrospun, short nanowire, and smooth poly(e-caprolactone) scaffolds to the subretinal space of porcine eyes. Stem Cells Int. 2012;2012:454295.
60. Bernards DA, Lance KD, Ciaccio NA, Desai TA. Nanostructured thin film polymer devices for constant-rate protein delivery. Nano Lett. 2012;12(10):5355-5361.
61. Liu Y, Wang R, Zarembinski TI, et al. The application of hyaluronic acid hydrogels to retinal progenitor cell transplantation. Tissue Eng Part A. 2013;19(1-2):135-142.
62. Ma J, Kabiel M, Tucker BA, Ge J, Young MJ. Combining chondroitinase ABC and growth factors promotes the integration of murine retinal progenitor cells transplanted into Rho(-/-) mice. Mol Vis. 2011;17:1759-1770.
63. Yao J, Tucker BA, Zhang X, Checa-Casalengua P, Herrero-Vanrell R, Young MJ. Robust cell integration from cotransplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials. 2011;32(4): 1041-1050.
64. Robinson R, Viviano SR, Criscione JM, et al. Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery. ACS Nano. 2011;5(6):4392-4400.
65. Zhu X, Su M, Tang S, et al. Synthesis of thiolated chitosan and preparation nanoparticles with sodium alginate for ocular drug delivery. Mol Vis. 2012;18:1973-1982.
66. Jayaraman MS, Bharali DJ, Sudha T, Mousa SA. Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Mol Vis. 2012;18: 2300-2308.
67. Fulgêncio Gde O, Viana FA, Ribeiro RR, Yoshida MI, Faraco AG, Cunha-Júnior Ada S. New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation. J Ocul Pharmacol Ther. 2012;28(4):350-358.
68. Wang TJ, Wang IJ, Lu JN, Young TH. Novel chitosanpolycaprolactone blends as potential scaffold and carrier for corneal endothelial transplantation. Mol Vis. 2012;18:255-264.
69. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.e41.
70. Hua J, Gross N, Schulze B, et al. In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. Mol Vis. 2012;18:1045-1054.
71. Barkana Y, Anis S, Liebmann J, Tello C, Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol. 2006;124(6): 793-797.
72. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol. 1999;43(suppl 1):S10-S16.
73. Wax MB, Camras CB, Fiscella RG, Girkin C, Singh K, Weinreb RN. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol. 2002;133(suppl):S1-S10.
74. Leonardi M, Pitchon EM, Bertsch A, Renaud P, Mermoud A. Wireless contact lens sensor for intraocular pressure monitoring: assessment on enucleated pig eyes. Acta Ophthalmol. 2009;87(4):433-437.
75. Mansouri K, Medeiros FA, Tafreshi A, Weinreb RN. Continuous 24-hour monitoring of intraocular pressure patterns with a contact lens sensor: safety, tolerability, and reproducibility in patients with glaucoma. Arch Ophthalmol. 2012; 130(12):1534-1539.
76. Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol Sci. 2009;110(1):138-155.
77. Hoet P, Legiest B, Geys J, Nemery B. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use? Drug Saf. 2009;32(8):625-636.
78. Ferreira L, Karp JM, Nobre L, Langer R. New opportunities: the use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell. 2008;3(2):136-146.
79. Magrez A, Kasas S, Salicio V, et al. Cellular toxicity of carbonbased nanomaterials. Nano Lett. 2006;6(6):1121-1125.
80. Zhu L, Chang DW, Dai L, Hong Y. DNA damage induced by multiwalled carbon nanotubes in mouse embryonic stem cells. Nano Lett. 2007;7(12):3592-3597.